Mesa Biotech Earns Additional BARDA Funding for Rapid COVID-19/Flu Test

Mesa Biotech announced that it has received an additional $13 million from HHS’ Biomedical Advanced Research and Development Authority (BARDA) for its single-sample Accula COVID-19/flu combination test.

The portable diagnostic uses Mesa’s Accula influenza A/B and respiratory syncytial virus testing platforms, both of which have received 510(k) marketing clearance from the FDA, and the company’s SARS-CoV-2 testing platform, which has received Emergency Use Authorization.

The test will deliver rapid polymerase chain reaction results in approximately 30 minutes in point-of-care settings, using a throat, nasal or nasopharyngeal swab sample, the company said.